EFSA's provisional safe-level guidance shakes up novel food compliance for hemp-derived products

EFSA’s February 2026 cannabidiol update has introduced a new reference point that could materially reshape the compliance landscape for hemp-derived ingestible products in the EU. On 9 February 2026, EFSA announced that its NDA Panel had established a provisional safe intake level for CBD of 0.0275 mg/kg weight/day, which works out to roughly 2 mg/day for a 70 kg adult. For a sector in which supplements, beverages, gummies, and fortified foods have often been positioned at much higher daily intakes, that figure is not a minor technical adjustment. It is a potential reset for formulation, exposure assessments, and authorization strategy.

The key point is that this is not a full scientific clearance for CBD as a novel food. EFSA paired the provisional level with a clear warning that persistent data gaps remain. That means the announcement is both a milestone and a complication: it gives regulators and businesses an interim risk benchmark, while also confirming that many dossiers may still struggle unless they address unresolved safety questions with much stronger evidence.

A provisional CBD ceiling with immediate market consequences

The new provisional safe intake level matters because the European Commission continues to treat CBD, in non-medical use, as a novel food provided EU novel food rules are met. In practical terms, that ties EFSA’s updated benchmark directly to market access for hemp-derived ingestibles containing isolated or enriched CBD. If a product concept is built around daily intakes far above about 2 mg/day for an average adult, the compliance implications are immediate and potentially severe.

Many existing or historical hemp-food concepts were designed around much higher CBD serving sizes. EFSA’s own 2025 opinion on a synthetic CBD novel food, for example, reviewed proposed uses in food supplements at up to 150 mg/day. Against the 2026 provisional safe intake of roughly 2 mg/day, the difference is dramatic. It illustrates the growing mismatch between prior commercial assumptions and the current direction of EU risk assessment.

For product developers, the practical outcome is stark. Formulas may need to be reduced, serving sizes rethought, labels revised, and intended uses narrowed. In some cases, companies may conclude that a dossier built around older intake assumptions is no longer commercially or scientifically viable without substantial redesign. The result is a likely wave of reformulation and dossier rebuilding across the hemp-derived product category.

Why EFSA’s update is not a green light

It is tempting to read the 2026 statement as long-awaited regulatory certainty, but that would be a mistake. EFSA explicitly said it had established a provisional safe intake level for CBD as a novel food but highlighted persistent data gaps. That phrasing is crucial because it signals that the underlying scientific concerns are not resolved. The number provides a risk-management anchor, not a clean bill of health.

This position is consistent with EFSA’s earlier 2022 statement, when the authority said it could not establish the safety of CBD as a novel food based on the evidence then available. At that time, EFSA noted there were 19 applications under assessment and concluded that the data were insufficient. The 2026 update should therefore be understood as a partial advance in assessment methodology rather than a final settlement of the science.

For applicants, that distinction changes the burden of proof. A company cannot assume that simply formulating below the provisional intake will secure approval. EFSA’s message is that the safety database remains incomplete, and dossiers still need to address unresolved hazards convincingly. In other words, compliance is not only about hitting a lower exposure number; it is also about closing the scientific gaps that EFSA keeps identifying.

The unresolved endpoints still driving novel food scrutiny

EFSA’s core toxicological concerns have remained remarkably consistent. In 2022, the authority said the effects of CBD on the liver, gastrointestinal tract, endocrine system, nervous system, and psychological function required clarification. In 2026, EFSA reiterated that previously identified gaps remain, including possible effects on the liver and the endocrine, nervous, and reproductive systems. That continuity matters because it shows that the scientific objections are not narrow or temporary.

These endpoints sit at the heart of novel food dossier strategy. Applicants will need to show that their ingredient, specification, intake scenario, and target population do not create unacceptable uncertainty around liver toxicity, endocrine disruption, neurological effects, reproductive risks, gastrointestinal outcomes, or psychological impacts. A weak evidence package on any of these areas can undermine the credibility of the whole application.

The persistence of these concerns also helps explain why the provisional intake is so conservative. When regulators see multiple unresolved endpoints rather than one isolated hazard, they tend to apply a more cautious approach. That has major consequences for hemp-derived products because the burden is no longer just to explain what CBD is, but to demonstrate why long-term intake at the proposed levels is adequately characterized across several sensitive biological systems.

Novel food status: hemp seed foods and CBD are not the same thing

One of the most important compliance distinctions in the sector is the difference between traditional hemp seed foods and isolated CBD ingredients. According to a European Commission application summary, hemp seed, hemp seed oil, hemp seed flour, and defatted hemp seed have a history of consumption in the EU and therefore are not novel. Isolated CBD, by contrast, was not consumed to a significant degree before 15 May 1997 and can therefore be considered novel.

This distinction is critical because some businesses still try to position CBD-rich products under the halo of conventional hemp foods. That approach is increasingly risky. A product based on traditional hemp seed ingredients may fall outside the novel food regime if it genuinely reflects historical use, but an ingestible formulated with isolated or enriched CBD will usually face a very different regulatory analysis. EFSA’s new provisional safe level therefore lands most heavily on products that concentrate, isolate, or intentionally enrich cannabinoids.

Companies should also avoid overreliance on the EU Novel Food Status Catalogue. The Commission is explicit that the catalogue is a non-binding tool based on information from Member States. It can be useful as a signal, but it is not a legal shield. For hemp operators, that means catalogue references should support, not replace, a robust novel food position backed by technical evidence, product characterization, and where relevant, a defensible history-of-use file.

Approval remains difficult, and the termination record proves it

Even before the 2026 CBD update, the authorization pathway for cannabinoid novel foods was already looking difficult. The European Commission’s decisions terminating procedures show repeated attrition across cannabidiol-related files in 2022, 2023, 2024, and 2026. The affected dossiers include cannabidiol, CBD isolate, CBD oil, Cannabis sativa L. extracts, hemp oil extract containing cannabinoids, and synthetic cannabidiol. That pattern does not resemble a steadily maturing approval pipeline; it looks more like a bottleneck with frequent exits.

The 2024 record is especially telling. Commission records show multiple CBD-related procedure terminations on 11 September 2024, including files NF 2020/1658, 2020/1657, 2020/1921, 2020/1659, and 2020/1938. The same page also lists 31 July 2024 terminations for synthetic cannabidiol and cannabidiol from Cannabis sativa L. This means the compliance shock did not begin with EFSA’s 2026 provisional level. The new threshold has arrived on top of an already restrictive and fragile authorization environment.

The trend has continued into 2026. The Commission logged a 20 February 2026 decision terminating a procedure for hemp (Cannabis sativa L.) and a 27 March 2026 termination for synthetic cannabidiol. For businesses looking at the market as of 22 April 2026, the message is clear: novel food approval for hemp-cannabinoid products remains highly challenging, and EFSA’s provisional CBD benchmark is likely to intensify that challenge rather than relieve it.

Dossier quality now matters even more than formulation

The science-to-serving mismatch is only part of the story. Procedure management and dossier responsiveness are also decisive. EFSA’s summary of the synthetic CBD opinion notes that the applicant did not reply to EFSA’s latest request in June 2022 for additional data. That detail is a useful cautionary example for compliance teams: even a commercially attractive ingredient can fail if the data package is incomplete or the applicant does not engage effectively with regulator questions.

This procedural lesson becomes more important under EFSA’s updated administrative expectations. EFSA has stated that its updated guidance for novel food applications applies to all applications submitted to the European Commission starting in February 2025. As a result, hemp-derived product applicants are dealing not only with a stricter CBD risk benchmark, but also with a newer framework for dossier preparation and evidence presentation.

That combination raises the bar substantially. Companies now need stronger toxicology, better human data, tighter exposure modelling, and more disciplined regulatory project management. Internal alignment between R&D, quality, legal, toxicology, and regulatory affairs is likely to become a basic requirement rather than a best practice. In the current climate, a novel food application that is underpowered scientifically or weak operationally faces long odds.

Broader cannabinoid scrutiny increases pressure on hemp products

The CBD issue does not exist in isolation. EFSA’s broader approach to cannabinoids shows a tightening stance on hemp-related exposure control more generally. On 18 November 2025, EFSA addressed delta-8 THC and concluded that the acute reference dose for the combined intake of delta-8 THC and delta-9 THC is 1 microgram/kg weight/day. That signals that cannabinoid exposure from hemp foods is being examined across the spectrum, not only for CBD.

This matters especially for full-spectrum and broad-spectrum hemp products, where CBD may coexist with trace or measurable levels of THC-related compounds. A business that focuses only on CBD dosage while neglecting THC carryover could still face serious compliance risk. The German Federal Institute for Risk Assessment, BfR, has long warned that THC exposure from hemp foods can exceed EFSA’s acute reference dose, particularly with hemp seed oil containing high THC contents.

BfR also continues to reference older guidance values for THC in food categories, including 5 mg/kg for edible oils and 0.150 mg/kg for other foods, while emphasizing EFSA’s acute reference dose framework. That shows how national enforcement considerations can persist alongside EU novel food review. For manufacturers, the implication is straightforward: novel food compliance, contaminant management, and cannabinoid carryover control must be handled as one integrated strategy.

What companies should do next after EFSA’s 2026 statement

EFSA itself appears to recognize the significance of the new position. The authority scheduled a webinar on 21 April 2026 titled “Webinar on the risk assessment of cannabidiol as a novel food,” with agenda items including the updated statement, its impact, and future steps. The wording is revealing. When “impact” and “future steps” become formal discussion topics, businesses should assume that the February 2026 statement is expected to shape ongoing assessments and applicant strategy in real time.

For operators in the hemp-derived products sector, the immediate priority should be portfolio triage. Companies should identify which products contain isolated or enriched CBD, compare labelled and foreseeable daily intakes against EFSA’s provisional safe intake, and assess whether reformulation or serving-size reduction is realistic. At the same time, they should review whether the product could genuinely rely on traditional hemp seed food status or whether it clearly falls into the novel food category.

The second priority is scientific and procedural gap analysis. Applicants should map their evidence against EFSA’s unresolved endpoints, test whether their exposure assumptions remain defensible, and evaluate dossier completeness under the post-February 2025 guidance regime. Where files are weak, a strategic pause may be wiser than pressing a with legacy assumptions. In 2026, the companies most likely to succeed will be those that accept the new compliance reality early and rebuild accordingly.

EFSA’s provisional safe intake for CBD has changed the conversation around hemp-derived products in Europe. It compresses the room for product design, sharpens the focus on toxicological uncertainty, and reinforces the distinction between traditional hemp seed foods and cannabinoid-enriched novel foods. Just as importantly, it arrives in a regulatory environment already marked by repeated terminations and an increasingly demanding evidentiary standard.

For the hemp sector, this is not the end of the CBD novel food story but the start of a more exacting chapter. Businesses that continue to rely on outdated dosage norms, informal catalogue comfort, or incomplete dossiers may find the EU pathway narrowing further. Those that treat EFSA’s 2026 statement as a trigger for reformulation, stronger science, and more disciplined regulatory strategy will be better placed to navigate the next phase of novel food compliance for hemp-derived products.